MorphoSys, US Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$1.8M
Doctors Paid
4,370
Transactions
9,037
2024 Total
$87,873
Payment Breakdown by Category
Consulting$812,641 (44.4%)
Research$251,773 (13.8%)
Food & Beverage$177,881 (9.7%)
Travel$11,510 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $812,641 | 216 | 44.4% |
| Grant | $400,000 | 2 | 21.9% |
| Unspecified | $251,773 | 52 | 13.8% |
| Food and Beverage | $177,881 | 8,651 | 9.7% |
| Space rental or facility fees (teaching hospital only) | $161,725 | 43 | 8.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,796 | 9 | 0.7% |
| Travel and Lodging | $11,510 | 56 | 0.6% |
| Education | $118.26 | 8 | 0.0% |
Payments by Type
General
$1.6M
8,985 transactions
Research
$251,773
52 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Research Infrastructure to Promote the Enrollment of Minority Patients on Clinical Trials: The Lymphoma Integrated Network for access to Clinical Trials for Under-represented Populations (LINCT-UP) | $200,000 | 0 | 1 |
| A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL) | $28,328 | 0 | 31 |
| A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed diffuse large B-cell lymphoma (DLBCL) | $14,488 | 0 | 8 |
| realMIND: A Multicenter, Observational Study to Characterize the Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in US Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma With a Focus on Racial and Ethnic Minority Patients | $5,896 | 0 | 7 |
| A Phase II/III, Randomised, Multicentre Study of MOR00208 with Bendamustine versus Rituximab with Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R-R DLBCL) Who Are Not Eligible for High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT) ? B-MIND | $3,061 | 2 | 5 |
Payments by Medical Specialty
Top Paid Doctors — Page 5
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Faisal Musa, Md, MD | Hematology & Oncology | Dearborn, MI | $1,467 | $0 |
| Dr. Sashi Naidu, M.d, M.D | Hematology & Oncology | Rock Hill, SC | $1,466 | $0 |
| Dr. Steven Hager, D.o, D.O | Hematology & Oncology | Fresno, CA | $1,457 | $0 |
| Rangaswamy Chintapatla, M.d, M.D | Medical Oncology | Kennewick, WA | $1,455 | $0 |
| Dr. James Essell, Md, MD | Hematology & Oncology | Cincinnati, OH | $1,455 | $0 |
| Mr. James Dugan, Md, MD | Internal Medicine | Winston Salem, NC | $1,455 | $0 |
| Carole Miller, Md, MD | Medical Oncology | Baltimore, MD | $1,455 | $0 |
| Dr. Christopher Yasenchak, M.d, M.D | Hematology & Oncology | Eugene, OR | $1,455 | $0 |
| Mr. Neil Nagovski, Md, MD | Hematology & Oncology | Miami, FL | $1,455 | $0 |
| Jeffrey Letzer, Do, DO | Hematology & Oncology | Fort Wayne, IN | $1,455 | $0 |
| Dr. Ravi Kishore Narra, M.d.,, M.D., | Hematology & Oncology | Menomonee Falls, WI | $1,455 | $0 |
| Mohammed Bukari, Md, MD | Hospitalist | Clovis, CA | $1,448 | $0 |
| Dr. Gustavo Fonseca, Md, MD | Hematology | Lecanto, FL | $1,440 | $0 |
| Dr. Christina Poh, M.d, M.D | Hematology & Oncology | Duarte, CA | $1,440 | $0 |
| Dr. Bramham Reddy, M.d, M.D | Hematology & Oncology | Lufkin, TX | $1,440 | $0 |
| Bei Hu, Md, MD | Hematology & Oncology | Charlotte, NC | $1,440 | $0 |
| Dr. Waqas Jehangir, Md, Mbbs, MD, MBBS | Hospice and Palliative Medicine | Sioux Falls, SD | $1,440 | $0 |
| Dr. Leena Rahmat, M.d, M.D | Hematology & Oncology | Springfield, MA | $1,440 | $0 |
| Dr. Oscar Lahoud, M.d, M.D | Medical Oncology | Brooklyn, NY | $1,438 | $0 |
| Lucio Gordan, Md, MD | Hematology | Gainesville, FL | $1,338 | $0 |
| Dr. Alan Zausner Skarbnik, Md, MD | Hematology & Oncology | Charlotte, NC | $1,338 | $0 |
| Solly Chedid, M.d, M.D | Hematology & Oncology | Pascagoula, MS | $1,293 | $0 |
| Dr. Danko Martincic, Md, MD | Hematology | Post Falls, ID | $1,195 | $0 |
| Narendranath Epperla, Md, MD | Internal Medicine | Columbus, OH | $1,180 | $0 |
| Sreenivasa Nattam, Md, MD | Medical Oncology | Fort Wayne, IN | $1,180 | $0 |
Ad
Top Products
- MONJUVI $1.5M
- Monjuvi $11.25
Payment Categories
- Food & Beverage $177,881
- Consulting $812,641
- Travel & Lodging $11,510
- Research $251,773
About MorphoSys, US Inc.
MorphoSys, US Inc. has made $1.8M in payments to 4,370 healthcare providers, recorded across 9,037 transactions in the CMS Open Payments database. In 2024, the company paid $87,873. The top product by payment volume is MONJUVI ($1.5M).
Payments were distributed across 83 medical specialties. The top specialty by payment amount is Hematology & Oncology ($692,644 to 1,208 doctors).
Payment categories include: Food & Beverage ($177,881), Consulting ($812,641), Research ($251,773), Travel & Lodging ($11,510).